CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 50 enrolled
Drug / intervention
Ketamine 1 Mg/mL-NaCl 0.9% Intravenous Solutiondrug
Likely dose
Ketamine 1 Mg/mL-NaCl 0.9% Intravenous Solutionfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06236113
NCT06236113Phase 4Completed

Low Dose Ketamine for Blunt Thoracic Trauma: A Prospective Randomized Trial

North Memorial Health Care·interventional·Posted Feb 1, 2024·Updated May 21, 2024

In Brief

A Phase 4 clinical trial evaluating Ketamine 1 Mg/mL-NaCl 0.9% Intravenous Solution for Blunt Injury of Thorax and Multiple Rib Fractures, Involving Three Ribs. Completed, enrolled 50 participants across 1 site.

Detailed Summary

The goal of this Randomized controlled double-blinded trial is to compare the addition of a ketamine infusion to placebo, when added to standard care in adult blunt trauma patients with multiple rib fractures. The main question it aims to answer are: • addition of low dose ketamine infusion (LDKI) decreases narcotic use • does LDKI impact pulmonary complications, readmission, or hospital length of stay Participants will receive usual standard of care with up to 48 hours of LDKI or placebo. If there is a comparison group: Researchers will compare infusion of a saline infusion to LDKI to see if LDKI decreases need for narcotic analgesics use.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20222023202420252026
First PostedFeb 1, 2024
Enrollment StartOct 1, 2021
Primary CompletionMar 19, 2023
Study CompletionJun 26, 2023
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 2.4 years ago

Interventions

Ketamine 1 Mg/mL-NaCl 0.9% Intravenous Solutiondrug

administered at rate of 0.1 mg/kg/hr